Clinical trial · Interventional
A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer
A Trail of Neoadjuvant Endostar in Combination With Docetaxel, Epirubicin and Cyclophosphamide in Patients With Stage III Breast Cancer (TENDENCY)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The trial was designed to study the efficacy and safety of neoadjuvant docetaxel, epirubicin in combination with cyclophosphamide(DEC) plus human recombinant endostatin (endostar) for breast cancer patients. The hypothesis of this protocol is that the combined an active angiogenesis agent to chemotherapy could enhance the pathological responce rate and further benefit breast cancer patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Stage III Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| docetaxel, epirubicin and cyclophosphamide | Drug | — | UNRESOLVED |
| docetaxel, epirubicin and cyclophosphamide plus endostar | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Chemo plus Endostar
- description
- Docetaxel, epirubicin and cyclophosphamide plus endostar
- interventionNames
- Drug: docetaxel, epirubicin and cyclophosphamide plus endostar
- type
- ACTIVE_COMPARATOR
- label
- Chemo only
- description
- docetaxel, epirubicin and cyclophosphamide
- interventionNames
- Drug: docetaxel, epirubicin and cyclophosphamide
Primary outcomes (1)
- measure
- Clinical/pathological response
- timeFrame
- 48 months
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed invasive breast cancer (core needle biopsy for breast cancer diagnosis and fine needle aspiration for lymph node metastasis diagnosis) * Age 18-70 * No evidence of distant metastasis * No previous therapy * Normal hematologic function * No abnormality of renal or liver function * Written informed consent Exclusion Criteria: * With allergic constitution or possible allergic reflection to drugs to be used in this study * Any concurrent uncontrolled medical or psychiatric disorder * History of severe heart diseases, including congestive heart failure, unstable angina, uncontrolled arrhythmia, myocardial infarction, uncontrolled high blood pressure, or heart valve disease * Being pregnant or nursing
References
Publications (0)
Data not yet available